About
Patient Care
Education
Research
Community
Friday, September 6& Saturday, September 7, 2024
In-personArnold and Mabel Beckman Center 100 Academy Way, Irvine, CA 92617
PLEASE NOTE: To claim your CME credits, you will need to create a CloudCME account and profile. The deadline to claim your CME credits is October 8, 2024. This is the only way to confirm your attendance, which is required in order to receive CME credit. For specific instructions on how to create a CloudCME account and profile, claim credits and download certificate, please click below.
HOW TO CLAIM CME CREDITS
If you should have any questions, please email the CME department at cme@hs.uci.edu
Accreditation Statement: The University of California, Irvine School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement:The University of California, Irvine School of Medicine designates this live activity for a maximum of 9 AMA PRA Category 1 Credits™. Physicians should claim only the credit that is commensurate with the extent of the participation in the activity.
Course Director: Olivia Lee, MD; Instructors: Soroosh Behshad, MD; Daniel Chang, MD; Sam Garg, MD; Sanjay Kedhar, MD; Olivia Lee, MD; Matthew Wade, MD
Baruch D. (Barry) Kuppermann, MD, PhD
Moderator: Barry Kuppermann, MD, PhD
What is home OCT and how can it help patients with wet AMD? Speaker: Christina Weng, MD, MBA
Ellipsoid zone: the new FDA-approved clinical endpoint Speaker: Andrew Browne, MD, PhD
Radiation retinopathy: current management and future strategies Speaker: Kapil Mishra, MD
Moderator: Stephanie Lu, MD
Panel discussion: Topics: wet and dry AMD; diabetic retinopathy, vein occlusions, uveitis, intravitreal injections in the management of geographical atrophy Panel: Andrew Browne, MD, PhD; Barry Kuppermann, MD, PhD; Christina Weng, MD; Kapil Mishra, MD; Mitul Mehta, MD; Mohammad Riazi, MD; Stephanie Lu, MD
Gavin Herbert Lecture: How gene therapy could transform retinal care Speaker: Christina Weng, MD, MBA
Moderator: Sanjay Kedhar, MD; Vivek Patel, MD
The wild west: Neuro-ophthalmology and Uveitis Panel: Wade Crow, MD; Lilangi Ediriwickrema, MD; Sanjay Kedhar, MD; Olivia Lee, MD; Vivek Patel, MD; Sam Spiegel, MD; Christina Weng, MD
Moderator: Soroosh Behshad, MD
Refractive surgery showdown: LASIK, SMILE, ICL, and more Panel: Soroosh Behshad, MD; Daniel Chang, MD; Sam Garg, MD; Matthew Wade, MD
Moderator: Matthew Wade, MD
Pearls and pitfalls from learning the iris implant Speaker: Matthew Wade, MD
IOL optics and range of focus IOLs: How to approach new technology Speaker: Daniel Chang, MD
Ocular surface transplantation - The Gavin Herbert Eye Institute Experience Speaker: Soroosh Behshad, MD
The only talk on dry eye and blepharitis you need to hear Speaker: Sam Garg, MD
Experience and outcomes in treating neurotrophic keratitis with cenergermin Speaker: Olivia Lee, MD
Steinert Memorial Lecture: A paradigm for presbyopia correction: starting with the why Speaker: Daniel Chang, MD
Moderator: Charlotte Gore, MD
Cornea | Speaker: Sam Garg, MD
Neuro-ophthalmology | Speaker: Sam Spiegel, MD
Retina | Speaker: Andrew Browne, MD, PhD
Pediatrics | Speaker: Charlotte Gore, MD
Glaucoma | Speaker: Andrew Smith, MD
Cataract | Speaker: Daniel Chang, MD
Oculoplastics | Speaker: Seanna Grob, MD
Refractive | Speaker: Matthew Wade, MD
Uveitis | Speaker: Sanjay Kedhar, MD
Lilangi Ediriwickrema, MD
Introduction to clinical informatics Speaker: Sally Baxter, MD, MSc
Moderator: Jeremiah Tao, MD
Brow lifting tips: improving vision through facial rejuvenation | Speaker: Lilangi Ediriwickrema, MD
Insights into treatment of unresectable periocular tumors | Speaker: Seanna Grob, MD
Pearls for lower eyelid reconstruction | Speaker: Jeremiah Tao, MD
Biostatistics for the ophthalmologist Speaker: Sally Baxter, MD, MSc
Moderator: Austin Fox, MD
Drug delivery systems for glaucoma | Speaker: Ken Lin, MD
Principles of managing the conjunctiva in glaucoma surgery | Speaker: Andrew Smith, MD
State of the bleb | Speaker: Austin Fox, MD
Cannabis and glaucoma: exploring therapeutic potential and challenges | Speaker: Sameh Mosaed, MD
Moderator: Sam Garg, MD
Retina | Speaker: Christina Weng, MD
General | Speaker: Sally Baxter, MD, MSc
Strabismus | Speaker: Donny Suh, MD
Barry Kuppermann, MD, PhD
Program Chair
Parking is free
Alcon
We Are Alcon We help the world see, look and feel better. And after our first 70 years, we are just getting started. Discover our story. Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 20,000 associates are enhancing the quality of life through innovative products, partnerships with eye care professionals and programs that advance access to quality eye care.
Ani Pharmaceuticals
ANI Pharmaceuticals is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceutical products. We are focused on building a successful Purified Cortrophin® Gel franchise, strengthening our generics business and established brands, and leveraging our North American manufacturing capabilities. For more information, please visit www.anipharmaceuticals.com or www.cortrophin.com.
Apellis
Apellis is a global biopharmaceutical company that leverages courageous science and creativity. We are committed to addressing the unmet needs of patients and eye care professionals worldwide.
Astellas
Astellas is a pharmaceutical company dedicated to improving the health of people around the world by identifying, developing, and delivering next generation treatments.
Bausch & Lomb
Bausch + Lomb is a global eye health organization with core businesses in over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry.
CorneaGen
CorneaGen is a mission-driven company committed to transforming how corneal surgeons treat and care for the cornea. Based in Seattle, the company is innovating the next generation of cornea care, from new medical devices and biologics to therapeutics and interventions. CorneaGen supports corneal surgeons and their patients with a spectrum of services, including the latest products, delivery of the highest-quality tissue, surgeon education, and advocacy for patient access and reimbursement policies.
Dompé
Dompé is an Italian biopharmaceutical company with a 130-year legacy of medical innovation. Based in Milan with US headquarters in the San Francisco Bay Area. Dompé is committed to medical and scientific advancements that address unmet medical needs in the areas of ophthalmology, transplants, oncology, and diabetes. To learn more about Dompé, email USMedinfo@dompe.com
Genentech
Genentech, a member of the Roche Group, has more than 40 years of experience in the field of biotechnology. Genentech is researching and developing new treatments for people living with a range of eye diseases that cause significant visual impairment and blindness, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), geographic atrophy (GA), and other retinal diseases.
Glaukos
Glaukos is committed to investing in the future of ophthalmology to transform standards of care and improve patient lives. We’ve achieved many firsts in clinical studies and over the past several years, Glaukos has reinvested approximately 30% of all sales back into research and development activities – all to relentlessly advance our goal of creating and delivering transformative therapies for patients struggling with eye diseases and the skilled surgeons dedicated to their healing. Innovation is at the core of everything we do. Our mission at Glaukos is to truly transform vision by pioneering novel, dropless platforms that can meaningfully advance the standard of care and improve outcomes for patients suffering from sight-threatening chronic eye diseases. Our mantra “We’ll Go First” embodies our commitment and determination to take chances and push the limits of science and technology to disrupt and improve the legacy treatment paradigms in glaucoma, corneal disorders, and retinal diseases.
Johnson & Johnson
At Johnson & Johnson Vision, we have a bold ambition: to change the trajectory of eye health. Through our operating companies, we've developed solutions for every stage of life-to help people see better, connect better and live better. We partner with eye care professionals to provide some of the world's leading products and technologies to address refractive error, cataracts, dry eye, and beyond. We are committed to using our reach and size for good and strive to put quality eye care within reach of everyone, everywhere. Click logo to watch video.
Sandoz
Sandoz is the leading global provider of off-patent medicines. These generic and biosimilar medicines are more affordable than reference medicines. With a comprehensive portfolio of around 1,500 products covering most major therapeutic areas and available in over 100 countries, we make a real difference for patients and healthcare systems worldwide.
STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL,” which includes the EVO ICL™ product line. More than 2,000,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: EVOICL.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company’s website at www.staar.com.
Tarsus Pharmaceuticals, Inc
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. The company is studying two investigational medicines in clinical trials. Its lead product candidate, XDEMVEY, is a novel therapeutic being studied in a second Phase 3 pivotal trial for the treatment of Demodex blepharitis. XDEMVEY is also being developed for the treatment of Meibomian Gland Disease. Tarsus is developing TP-05, an oral, non-vaccine therapeutic for the prevention of Lyme disease, which is currently being studied in a Phase 1 clinical trial.
Zeiss
With a special focus on ophthalmology, ophthalmic surgery and visualization systems in the field of microsurgery, ZEISS Medical Technology supports healthcare professionals in setting new standards of care with proven medical technology and broad application competence based on cutting-edge innovations.
This event is supported in part by educational grants from:
Regeneron
Click registration button to see further details for
Event Contact:
Dana Collinson | 949-824-7243 | dana.collinson@hs.uci.edu